Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
D001161:Arteriosclerosis / Q000097:blood; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy; D004176:Dipyridamole / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy; D007688:Kidneys, Artificial; D008297:Male; D012826:Silicone Elastomers / Q000009:adverse effects; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*; D014652:Vascular Diseases / Q000188:drug therapy
D004338:Drug Combinations; D012826:Silicone Elastomers; D006886:Hydroxychloroquine; D004176:Dipyridamole; D002994:Clofibrate; D001241:Aspirin; D013442:Sulfinpyrazone